Detection of recurrent malignant melanoma with 99mTc-MIBI scintigraphy

Melanoma Research

Volumn 8, Issue 4, 1998, Pages 355-360

  Alonso, O ^a   Martinez, M ^a   Mut, F ^a   Delgado, L ^a   Lago, G ^a   De Boni, D ^a   Bazzano, C ^a   Nunez M ^a   Garces M ^a   Muse, I M ^a   Roca, R ^a   Touya, E ^a   Espasandin J ^b   Priario, J ^a  

^a UNIVERSITY OF URUGUAY   (Uruguay)

^b National Institute of Oncology   (Uruguay)

Author keywords

99mTc MIBI; Melanoma; Metastatic disease

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; DEMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; RADIOIMMUNOASSAY; WHOLE BODY SCINTISCANNING;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; BRAIN NEOPLASMS; BREAST NEOPLASMS; DIGESTIVE SYSTEM NEOPLASMS; EVALUATION STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; RADIOIMMUNODETECTION; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; TECHNETIUM TC 99M SESTAMIBI;

EID: 7344235345     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-199808000-00009     Document Type: Article

References (31)

1. Morton DL, Wong JH, Kirkwood JM, Parker RG. Malignant melanoma. In: Holland J, Frei M, Bast R, eds. Cancer Medicine. Malvern: Lea & Febiger, 1993: 1793-1820.
2. Bassères N, Grob JJ, Richard MA, Thirion X, Zarour H, Noe C, Collet-Vilette AM, Lota I, Bonerandi JJ. Cost-effectiveness of surveillance of stage I melanoma. Dermatology 1995; 191: 199-203.
3. Jillela A, Mani S, Nair B. The role for close follow-up in melanoma patients with AJCC stages I-II: a preliminary analysis. Proc Annu Meet Am Soc Clin Oncol 1995; 14: 413(abstract).
4. Buzaid AC, Sandler AB, Mani S. Role of computed tomography in the staging of primary melanoma. J Clin Oncol 1993; 11: 638-643.
5. Villanueva-Meyer J, Leonard MH, Briscoe E, Cesani SA, Rhoden AS, Hove M, Cowan D. Mammoscintigraphy with technetium-99m-sestamibi in suspected breast cancer. J Nucl Med 1996; 37: 926-930.
6. Alonso O, Lago G, Mut F, Hermida JC, Núñez, M, De Palma G, Touya E. Thyroid imaging with Tc-99m MIBI in patients with solitary cold single nodules on pertechnetate imaging. Clin Nucl Med 1996; 21: 363-367.
7. Abdel-Dayem HM, Scott AM, Macapinlac HA. Role of 201-Tl chloride and 99m-Tc sestamibi in tumor imaging. In: Freeman LM, ed. Nuclear Medicine Annual. New York: Raven Press, 1994: 181-234.
8. Chiti A, Maffioli LS, Infante M, Grasselli G, Incarbone M, Gasparini MD, Savelli G, Bombardieri E. Assessment of mediastinal involvement in lung cancer with technetium-99m-sestamibi SPECT. J Nucl Med 1996; 37: 938-942.
9. Alonso O, Martinez M, Lago G, Bazzano C, Saadoun A, Mut F, Delgado L, Espasandín J, Touya E. Scintigraphic detection of invasive cutaneous malignant melanoma with Tc-99m MIBI. Clin Nucl Med 1996; 21: 557-559.
10. Alonso O, Martinez M, Delgado L, Lago G. 99m-Tc-sestamibi uptake by malignant melanoma lesions. Nucl Med Commun 1996; 17: 542-543(letter).
11. Martínez, M. Alonso O, Delgado L, Bazzano C, Garcés M, Lago G, Priario J, Roca R, Espasandín J. Cutaneous malignant melanoma: scintigraphic detection of recurrent disease with Tc-99m MIBI. Eur J Dermatol 1997; 7: 433-435.
12. Alonso O, Martínez M, Delgado L, Lago G, Bazzano C, Mut F, Núñez M, Garcés M, Priario J, Muse I, Touya E, Tc-99m MIBI scintigraphy for nodal staging of primary malignant melanoma and evaluation of recurrent disease. Eur J Nucl Med 1997; 24: P354(abstract).
13. Perrot JL, Soler C, Tiffet O, Lanthier K, Boucheron S, Dubois F, Cambazard F. Detection of malignant melanoma metastases with 99m-Tc-sestamibi SPECT (single photon emission tomography) during follow-up of malignant melanoma in 17 patients. Eur J Dermatol 1996; 6: 505-508.
14. Piwnica-Worms D, Kronauge JF, Chiu ML. Uptake and retention of hexakis (2-methoxyisobutylisonitrile) technetium (I): mitochondrial and plasma membrane potential dependence. Circulation 1990; 82: 1826-1838.
15. Chen LB. Mitochondrial membrane potentials in lung cell. Annu Rev Cell Biol 1988; 4: 155-181.
16. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM. Functional imaging of multidrug-resistant P-glucoprotein with an organotechnetium complex. Cancer Res 1993; 53: 1-8.
17. Ciarmiello A, Del Vecchio S, Potena MI. Technetium-99m-sestamibi efflux and P-glycoprotein expression in human breast carcinoma. J Nucl Med 1995; 63(suppl): 129P(abstract).
18. Schadendorf D, Herfordt R, Czarnetzki BM. P-glycoprotein expression in primary and metastatic malignant melanoma. Br J Dermatol 1995; 132: 551-555.
19. Wackers FJ, Berman DS, Maddahi J, Watson DD, Beller GA, Strauss HW, Boucher CA, Picard M, Holman BL, Fridich R, Inglese E, Delaloye B, Bischof-Delaloye A, Camin L, McKusick K. Technetium-99m hexakis 2-methoxyisobutyl isonitrile: human biodistribution, dosimetry, safety, and preliminary comparison to thallium-201 for myocardial perfusion imaging. J Nucl Med 1989; 30: 301-311.
20. Greenstein DS, Rogers GS. Management of stage I malignant melanoma. Dermatol Surg 1995; 21: 927-937.
21. Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181: 193-201.
22. Karakousis CP, Velez A, Driscoll DL. Metastasectomy in malignant melanoma. Surgery 1994; 115: 295-301.
23. Steinert HC, Huch Böni RA, Buck A, Böni R, Berthold T, Marincek B, Burg G, von Schulthess GK. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 1995; 195: 705-709.
24. Damian DL, Fulham MJm Thompson E, Thompson JF. Positron emission tomography in the detection and management of metastatic melanoma. Melanoma Res 1996; 6: 325-329.
25. Feggi L, Indelli M, Pansini GC, Santini A, Prandini N, Virgili AR. Immunoscintigraphy in malignant melanoma: a five-year clinical experience. Nucl Med Commun 1993; 14: 145-148.
26. Boni R, Huch-Boni RA, Steinert H, Dummer R, Burg G, von Schulthess GK. Anti-melanoma monoclonal antibody 225.28S immunoscintigraphy in metastatic melanoma. Dermatology 1995; 191: 119-123.
27. Chatal JF. The advantages and limits of immunoscintigraphy in the diagnosis of tumoral recurrences. Int J Rad Appl Instrum B 1986; 13: 203-205.
28. Kirkwood JM, Myers JE, Vlock DR, Neuman R, Ariyan S, Gottschalk A, Hoffer P. Tomographic gallium-67 citrate scanning: useful new surveillance for metastatic melanoma. Ann Intern Med 1982; 97: 694-699.
29. Bradfield HA, Tauxe WN, Levine G, Kirkwood JM, Klein H, Mochizuki T. In-111 monoclonal antibody versus Ga-67 citrate and Tc-99m SC substruction in a patient with a malignant melanoma. Clin Nucl Med 1994; 19: 703-707.
30. Duman Y, Burak Z, Ercan MT, Dirlik A, Bilkay BC, Akin Y, Taner M, Bekdik CF. Clinical evaluation of metastases of malignant melanoma imaging with 99m-Tc-glutathione and 99m-Tc-anti-melanoma antibody: a comparative study. Nucl Med Commun 1995; 16: 927-935.
31. Rodot S, Darcourt J, Bussiere F, et al. A radiolabelled iodobenzamide for malignant melanoma staging. Melanoma Res 1994; 4: 307-312.